Acute myocardial damage with CoronoVIrus Disease 2019 (COVID-19) (case study)

• Maksim A. Babaev
• Petrushin M.A.
• Dubrovin I.A.
• Kostritсa N.S.
• Aleksandr A. Eremenko

Abstract

In 20% of cases, COronaVIrus Disease 2019 is characterized by a severe and very severe course, which is accompanied by pneumonia, acute respiratory distress syndrome, multiple organ dysfunctions. Complications related to the cardiovascular system occur in 20-25% and alone or together with respiratory failure are the cause of deaths in 40% patients with an unfavorable course of the disease. Acute myocardial damage (5-38%), caused in majority of cases by combination of causes: type 2 heart attack on the background of acute viral myocarditis and a cytokine storm; coronary thrombosis due to COVID-associated coagulopathy; vasoconstriction due to blockage of SARS-COV-2 ACE2 receptors and increased concentration of angiotensin II; hypoxia from respiratory failure, manifests itself as heart failure, cardiac arrhythmias (~20%) and/or sudden death (5-7%).

This clinical case demonstrates that in a patient at high risk (hypertension), despite the positive dynamics, after applying therapy with human monoclonal antibodies to the interleukin 6 receptor (sarilumab), sudden death occurred on the 8^th day of ICU stay, the cause of which was myocardial damage due to COVID.

Keywords:coronovirus, COVID-19, acute myocardial damage, multiple organ dysfunctions

References

1.    World Health Organization, Coronavirus disease 2019 (COVID-19): situation report, 121. 2020. P. 19.

2.    Madjid M., et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Mar 27.

3.    Russian Society of Cardiology. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2020: 25 (3): 1-20. (in Russian)

4.    Zadori N., et al. The negative impact of comorbidities on the disease course of COVID-19. Intensive Care Med. 2020: 1-3.

5.    Gopinathannair R., et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020: 1-8.

6.    Liu K., et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020; 133 (9): 1025-31.

7.    Guo T., et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar.

8.    Shi S., et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5 (7): 802-10.

9.    Al Jaroudi W.A., Hage F.G. Cardiovascular disease in the literature: a selection of recent original research papers. J Nucl Cardiol. 2020; 27 (3): 712-4.

10.    Tersalvi G., et al. Elevated troponin in patients with coronavirus disease 2019: possible mechanism. J Card Fail. 2020; 26 (6): 470-5.

11.    Mahajan K., Chandra K.S. Cardiovascular comorbidities and complications associated with corona-virus disease 2019. Med J Armed Forces India. 2020 May.

12.    Babapoor-Farrokhran S., et al. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020; 253: 117723.

13.    Driggin E., et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020; 75 (18): 2352-71.

14.    Iba T., et al. The unique characteristics of CO-VID-19 coagulopathy. Crit Care. 2020; 24 (1): 360.

15.    Huang C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10 223): 497-506.

16.    Zhou F., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10 229): 1054-62.

17.    Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (CO-VID-19): evidence from a meta-analysis. Prog Cardiovasc. Dis. 2020 Mar.

18.    Krittanawong C., et al. Coronavirus disease 2019 (COVID-19) and cardiovascular risk: a meta-analysis. Prog Cardiovasc Dis. 2020; 63 (3): 390-1.

19.    Gao L., et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020; 21 (1): 83.

20.    Smirnov V.P., Panysheva I.A. Cardiomyocyte pathomorphology in sudden cardiac death. In: Medicine: challenges of today: materials of the III International scientific conference. Moscow: Buki-Vedi, 2016: 43-6. (in Russian)

21.    Kochi A.N., et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020; 31 (5): 1003-8.

22.    Marijon E., et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. Lancet Public Health. 2020; 5 (8): e437-43.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)